Revenue
2024
2025
RenovoRx, Inc. (RNXT)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1M | $43,000 | — | — | — | — |
| Gross profit | $796,000 | $43,000 | — | — | — | — |
| Research & development | $6.3M | $6.0M | $5.7M | $4.3M | $3.0M | $2.4M |
| Operating expenses | $13.3M | $11.0M | $11.4M | $9.9M | $5.7M | $3.2M |
| Operating income | −$12.5M | −$11.0M | −$11.4M | −$9.9M | −$5.7M | −$3.2M |
| EBITDAderived | −$10.5M | −$11.0M | — | — | — | — |
| Net income | −$11.2M | −$8.8M | −$10.2M | −$9.9M | −$6.3M | −$3.8M |
| Basic EPSper diluted share | -$0.32 | -$0.40 | -$0.99 | -$1.09 | -$1.21 | -$1.72 |
| Diluted EPSper diluted share | -$0.32 | -$0.40 | -$0.99 | -$1.09 | -$1.21 | -$1.72 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 19, 2026Form 4 | VOLL MARKChief Financial Officer | BuyCommon Stock | 25.0K | $0.79 | $19.8K | 142.4K |
| Mar 20, 2026Form 4 | Marton LaurenceDirector | BuyCommon Stock · indirect | 9.7K | — | — | 9.7K |
| Mar 20, 2026Form 4 | Marton LaurenceDirector | BuyWarrants · derivative · indirect | 4.9K | — | — | 4.9K |
| Mar 20, 2026Form 4 | Bagai ShaunChief Executive Officer | BuyCommon Stock · indirect | 24.3K | — | — | 313.4K |
| Mar 20, 2026Form 4 | Bagai ShaunChief Executive Officer | BuyWarrants · derivative · indirect | 12.2K | — | — | 12.2K |